Literature DB >> 30186003

Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?

.   

Abstract

Entities:  

Year:  2018        PMID: 30186003      PMCID: PMC6118832     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


× No keyword cloud information.
  24 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics.

Authors:  Arden R Barry; Ricky D Turgeon
Journal:  Can J Hosp Pharm       Date:  2016-06-30

3.  Introduction.

Authors:  Robyn L Houlden
Journal:  Can J Diabetes       Date:  2018-04       Impact factor: 4.190

Review 4.  The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.

Authors:  Shawn Riser Taylor; Kira B Harris
Journal:  Pharmacotherapy       Date:  2013-06-06       Impact factor: 4.705

5.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

6.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

7.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Authors:  Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

8.  Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Authors:  Claire C J Dekkers; David C Wheeler; C David Sjöström; Bergur V Stefansson; Valerie Cain; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012.

Authors:  Bingcao Wu; Kelly Bell; Amy Stanford; David M Kern; Ozgur Tunceli; Suma Vupputuri; Iftekhar Kalsekar; Vincent Willey
Journal:  BMJ Open Diabetes Res Care       Date:  2016-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.